Skye Bioscience Stock Price, News & Analysis

Skye Bioscience (NASDAQ:SKYE) presented Phase 1b study results for nimacimab, their peripheral CB1-inhibiting antibody, at the EASD Annual Meeting. The study, conducted in subjects with metabolic-associated steatotic liver disease (MASLD), demonstrated favorable safety and tolerability profiles.

Key findings include no serious adverse events, no discontinuations due to adverse events, and notably, no neuropsychiatric safety signals. The drug showed predictable pharmacokinetics, low immunogenicity, and only mild, infrequent gastrointestinal side effects across multiple ascending dose cohorts.

The study, originally conducted by Bird Rock Bio (acquired by Skye in 2023), supports nimacimab's potential role in treating metabolic diseases, with the company awaiting topline results from their CBeyond™ Phase 2a obesity study.

Skye Bioscience (NASDAQ:SKYE) reported promising preclinical data for its CB1 inhibitor nimacimab in diet-induced obesity (DIO) mouse studies. The drug demonstrated superior weight loss efficacy compared to monlunabant and enhanced results when combined with tirzepatide, achieving over 40% weight loss.

Key findings show nimacimab's differentiation as a peripherally-restricted CB1 inhibitor with potential superior safety profile, ability to reduce post-treatment weight rebound by over 50%, and enhanced efficacy when combined with both low and high-dose tirzepatide. The company expects to report top-line Phase 2 CBeyond™ study data in late Q3/early Q4 2025.

Skye Bioscience (Nasdaq: SKYE) has announced the completion of the 26-week treatment phase in its Phase 2a CBeyond™ clinical trial evaluating nimacimab, a peripherally-restricted CB1 inhibitor antibody for obesity treatment. The study's primary endpoint will assess weight loss changes between nimacimab and placebo, with an exploratory arm examining the combination with semaglutide (Wegovy®).

The company has also completed enrollment for a 26-week extension study, which will provide data for a total treatment duration of 52 weeks, followed by a 13-week follow-up period. Topline data from the initial phase is expected in late Q3/early Q4 2025, while extension study results are anticipated in Q1 2026.

Skye Bioscience (NASDAQ:SKYE) has announced a virtual KOL event scheduled for September 4, 2025, at 8:00 AM ET. The event, titled "Expert Panel on Peripheral CB1 Inhibition as a Mechanism for Weight Loss," will focus on the upcoming topline results from the Phase 2a CBeyond™ trial of nimacimab, their first-in-class peripheral CB1 antibody for obesity treatment.

The event will feature distinguished obesity experts including Dr. Kevin Cannon, Dr. Sean Wharton, and Dr. Marcus Goncalves. Key discussion topics will include success criteria for the Phase 2a study, mechanism of peripheral CB1 inhibition, new preclinical data, and safety considerations including gastrointestinal and neuropsychiatric outcomes. While no clinical results will be previewed, the event aims to provide context for interpreting the upcoming data readout and nimacimab's potential role in obesity treatment.

Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech company focused on obesity and metabolic health disorders, has announced its participation in multiple upcoming conferences in September 2025.

The company will present at three major investment conferences: the Cantor Global Healthcare Conference (Sept. 5), the H.C. Wainwright Global Investment Conference (Sept. 8), and the Morgan Stanley Global Healthcare Conference (Sept. 10). Additionally, Skye will participate in two medical conferences: Obesity Science & Innovation in Boston and the EASD Annual Meeting in Vienna, where they will present data on nimacimab, their CB1 receptor antibody for MAFLD treatment.

Skye Bioscience (NASDAQ: SKYE) reported Q2 2025 financial results and key updates for its obesity treatment program. The company anticipates top-line data from its CBeyond™ Phase 2a study of nimacimab in late Q3/early Q4 2025, while patient enrollment has begun for the 26-week extension study. New preclinical data showed nimacimab's superior weight rebound profile compared to incretin therapy, with combination studies demonstrating enhanced weight loss of 44% when combined with tirzepatide.

Financial highlights include $48.6 million in cash as of June 30, 2025, expected to fund operations through Q1 2027. Q2 2025 saw R&D expenses of $14.3 million and a net loss of $17.6 million. The company has expanded its team to 20 employees and successfully manufactured its first batch of drug product since acquiring nimacimab.

Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech company specializing in obesity and metabolic health disorders, has scheduled its Q2 2025 earnings call for August 7, 2025, at 1:30 p.m. PT/4:30 p.m. ET.

The company will release its financial results and business update after market close on the same day. Investors can access the live webcast, earnings release, financial tables, and presentation materials through Skye's Investor Relations website. A replay will be available following the call.

Skye Bioscience (NASDAQ: SKYE) has unveiled its 'Anatomy of Progress' video series and presented preclinical data for nimacimab, its novel anti-obesity drug, at the American Diabetes Association's 85th Scientific Sessions. Nimacimab is a peripherally-restricted CB1 receptor antibody that remains over 99% excluded from the brain, potentially offering the same weight loss benefits as first-generation CB1 inhibitors without their neuropsychiatric side effects. The four-part video series details the drug's development, market positioning, and clinical progress. Preclinical data demonstrated significant weight reduction, improved metabolic homeostasis, and reduced obesity-induced inflammation in diet-induced obesity mouse models. The company also participated in an Evercore ISI panel discussing non-incretin obesity treatments, highlighting nimacimab's potential as both a standalone therapy and in combination with incretin-based drugs.

Skye Bioscience (NASDAQ: SKYE) will present new preclinical data for its CB1 inhibitor nimacimab at the American Diabetes Association's 85th Scientific Sessions from June 20-23, 2025, in Chicago. The company will showcase its research through multiple presentations including an Evercore panel, an Innovation Hub symposium, and a poster presentation. The symposium will focus on nimacimab's mechanism of action in weight loss and metabolic regulation, highlighting its potential as a non-incretin-based therapeutic option. The poster presentation will demonstrate nimacimab's effects on metabolic homeostasis in diet-induced obesity mouse models, showing promising results in weight loss, hormonal regulation, and inflammatory biomarker reduction. The research emphasizes peripheral CB1 inhibition as a safe approach to modulate metabolic parameters.